03.22.23
IFF, a supplier in the health and wellness industries, has achieved successful production of an anaerobic “next generation” probiotic strain at an industrial scale. This will support commercially viable innovation in the dietary supplements market for years to come, the company reports.
The newly-discovered and proprietary species of Akkermansia, considered by the company a “next-generation” probiotic due to its recent discovery and roles in insulin sensitivity, gut barrier function, and immunity, will be produced at the company’s manufacturing and R&D site at Dangé-Saint-Romain. Growth of “next-generation” probiotics has been slow due to challenges associated with the strains’ complex and specific nutritional requirements, IFF reports.
“We’ve made this breakthrough achievement thanks to our cutting-edge process development capabilities—which encompass small-scale, high-throughput and high-information tools—paired with our large-scale manufacturing skills and deep investments in our teams, facilities and certifications,” said Sebastian Stahl, director for process R&D at IFF. “Not only does the successful production of Akkermansia at industrial scale demonstrate that we have the know-how and technologies to identify promising microbiome solutions, but we’re also experts at establishing their safe and efficient production.”
“We are proud of this milestone in IFF’s history, and we are confident in our ability to commercialize our extensive microbiome pipeline, comprising in-house developments, as well as projects with external partners or customers,” said Sebastien Guery, vice president, health, IFF.
The newly-discovered and proprietary species of Akkermansia, considered by the company a “next-generation” probiotic due to its recent discovery and roles in insulin sensitivity, gut barrier function, and immunity, will be produced at the company’s manufacturing and R&D site at Dangé-Saint-Romain. Growth of “next-generation” probiotics has been slow due to challenges associated with the strains’ complex and specific nutritional requirements, IFF reports.
“We’ve made this breakthrough achievement thanks to our cutting-edge process development capabilities—which encompass small-scale, high-throughput and high-information tools—paired with our large-scale manufacturing skills and deep investments in our teams, facilities and certifications,” said Sebastian Stahl, director for process R&D at IFF. “Not only does the successful production of Akkermansia at industrial scale demonstrate that we have the know-how and technologies to identify promising microbiome solutions, but we’re also experts at establishing their safe and efficient production.”
“We are proud of this milestone in IFF’s history, and we are confident in our ability to commercialize our extensive microbiome pipeline, comprising in-house developments, as well as projects with external partners or customers,” said Sebastien Guery, vice president, health, IFF.
